Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ahmed Hamed Salem"'
Autor:
Ahmed Hamed Salem, Rajeev M. Menon
Publikováno v:
Clinical and Translational Science, Vol 17, Iss 5, Pp n/a-n/a (2024)
Abstract Venetoclax, a highly potent BCL‐2 inhibitor, is indicated for treatment of some hematologic malignancies as monotherapy, and/or in combination with other agents. Venetoclax pharmacokinetics has been extensively characterized in patients an
Externí odkaz:
https://doaj.org/article/c34b284b9fef4c09817c269c83003c9a
Autor:
Sathej Gopalakrishnan, Rajeev Menon, Ahmed A. Suleiman, Arnon P. Kater, Stephan Stilgenbauer, John F. Seymour, Brenda Chyla, Tong Lu, Su Young Kim, Andrew W. Roberts, Jennifer A. Woyach, Sven Mensing, Ahmed Hamed Salem
Publikováno v:
HemaSphere, Vol 7, Iss 12, p e983 (2023)
Externí odkaz:
https://doaj.org/article/a2f017128b0e46e6a3b38e44b5b505e7
Autor:
Amal Kamal Abdel-Aziz, Mona Kamal Saadeldin, Ahmed Hamed Salem, Safaa A. Ibrahim, Samia Shouman, Ashraf B. Abdel-Naim, Roberto Orecchia
Publikováno v:
Future Pharmacology, Vol 2, Iss 4, Pp 431-443 (2022)
Chloroquine (CQ) and hydroxychloroquine (HCQ) have been used to treat malaria and autoimmune diseases for more than 70 years; they also have immunomodulatory and anticancer effects, which are linked to autophagy and autophagy-independent mechanisms.
Externí odkaz:
https://doaj.org/article/97dbdeee71fc4ac1af5e79e835497a68
Autor:
Amr Alaarg, Rajeev Menon, David Rizzo, Yemin Liu, Jeffrey Bien, Tricia Elkinton, Timothy Grieme, Lutz R. Asmus, Ahmed Hamed Salem
Publikováno v:
Clinical and Translational Science, Vol 15, Iss 1, Pp 244-254 (2022)
Abstract This work presents an end‐to‐end approach for assessing the absolute bioavailability of highly hydrophobic, poorly water‐soluble compounds that exhibit high nonspecific binding using venetoclax as a model drug. The approach utilizes a
Externí odkaz:
https://doaj.org/article/1e832f7aa4554f67b6efa91901c6dfd9
Publikováno v:
Clinical and Translational Science, Vol 13, Iss 3, Pp 555-562 (2020)
Venetoclax is a cytochrome P450, family 3, subfamily A (CYP3A) substrate and was shown to inhibit P‐gp efflux transporters in vitro. To quantify the impact of CYP3A inhibition by ritonavir on venetoclax disposition and P‐gp inhibition by venetocl
Externí odkaz:
https://doaj.org/article/a4d3242e8ffb483bbd1d0ede6000f6af
Publikováno v:
Clinical and Translational Science, Vol 12, Iss 6, Pp 625-632 (2019)
Venetoclax is an approved drug for the treatment of some hematological malignancies. Venetoclax can cause reduction in B‐lymphocyte counts as an on‐target effect. The purpose of this analysis is to quantify the relationship between venetoclax exp
Externí odkaz:
https://doaj.org/article/44907fa90dd54107b7a9ad254526caea
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 8, Iss 3, Pp 138-145 (2019)
The use of model‐based drug development (MBDD) has been demonstrated to improve the efficiency of clinical trial design. However, MBDD complexity can limit its use, particularly early in clinical development. In this tutorial, a simple and generali
Externí odkaz:
https://doaj.org/article/80587ea9f63f437bb368f58da128977e
Autor:
Mohamed Badawi, Rajeev Menon, Andrew E. Place, Tammy Palenski, Gauri Sunkersett, Richard Arrendale, Rong Deng, Sara M. Federico, Todd M. Cooper, Ahmed Hamed Salem
Publikováno v:
Journal of Cancer. 14:1151-1156
Autor:
Jingqi Q. X. Gong, Ahmed A. Suleiman, Rajeev Menon, Rong Deng, Sven Mensing, Ahmed Hamed Salem
Publikováno v:
The Journal of Clinical Pharmacology.
Autor:
Mohamed Badawi, Xin Chen, Patrick Marroum, Ahmed A. Suleiman, Sven Mensing, Anette Koenigsdorfer, Julia Teresa Schiele, Tammy Palenski, Divya Samineni, David Hoffman, Rajeev Menon, Ahmed Hamed Salem
Publikováno v:
Clinical Drug Investigation. 42:657-668
Venetoclax is an approved BCL-2 inhibitor, currently under evaluation in different hematological malignancies in adult and pediatric populations. Venetoclax is available as 10, 50, and 100 mg tablets. To provide an alternative to patients who find ta